EXECUTIVE SUMMARY REPORT Pakistan Pharmaceutical Market

The report is for the exclusive use of the recipient and may not be reproduced in any form without the written consent from IMS. The information contained in the report is confidential and may not be divulged to any other party. Copyright IMS AG, ZUG Switzerland 2009

1st HALF 2010

2

Executive Summary Report

Pharmaceutical Market

The report is for the exclusive use of the recipient and may not be reproduced in any form without the written consent from IMS. The information contained in the report is confidential and may not be divulged to any other party. Copyright IMS AG, ZUG Switzerland 2009

1st HALF 2010

3

TABLE OF CONTENTS

Foreword by Dr. Aman Ullah Khan ……………………………………………………………………………04

World market

Company news in Brief ……………………………………………………………………………06 Global Pharmaceutical Sales ……………………………………………………………………………14

Pakistan Pharmaceutical Market

Market Overview ……………………………………………………………………………16 Multi-Vitamin Price Increase Analysis ……………………………………………………………………………21

Commentary ……………………………………………………………………………22 Tables ………………………………………………………………………PK 1-9

Client’s Feedback Form FORM ………………………………………………………………………………29

4

FOREWORD

We are once again proud to present you the year end Executive Summary report based on Q2 2010 with analysis of the Pakistan market. The importance of this report has been highlighted by our respective clients who have time and again requested for this year end report. IMS Health has always offered a unique solution to the Pharmaceutical industry through this report and has played an important role in delineating the industry trends. We would however, appreciate your valuable comments in the attached feedback form enabling us to further improve the quality and content of this report. Yours Sincerely,

Dr. Aman Ullah Khan Chief Executive Tel Off: 021-4315148 / 4383700 E-mail: akhan@pk.imshealth.com

5

WORLD MARKET

6

MARCH 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF MERGERS & ACQUISITIONS NOVARTIS is to buy US-based ORIEL in a bid to boost its portfolio of generic respiratory drugs. VALEANT announced two acquisitions, of a privately-held OTC and generics company in Brazil, and VITAL SCIENCE, a Canadian OTC dermatology firm. ABBOTT and WOCKHARDT terminated their deal through which the US giant was due to purchase the Indian manufacturer’s nutrition business; Wockhardt was unable some of its debt restructuring issues with overseas lenders. Licensing WARNER CHILCOTT amended its Actonel collaboration with SANOFI-AVENTIS (inherited with Procter & Gamble’s pharmaceutical unit) and will take full control of the osteoporosis drug in the US and Puerto Rico, while ATON acquired the US rights to BRISTOL-MYERS SQUIBB’s Parkinson’s therapy Lodosyn. TAKEDA licensed AMAG’s Feraheme anaemia drug in many territories outside of the US, while MERCK & CO gained the rights to MASSBIOLOGICS’ tetanus-diphtheria vaccine in the US. FERRING will co-promote XANODYNE’s Zipsor NSAID in the US, INVIDA is to commercialise IPSEN’s specialty care drugs in South-east Asia, and ESTEVE will co-market RECORDATI’s cholesterol therapy pitavastatin (licensed from KOWA) in Spain. Merck & Co is to co-promote NYCOMED’s COPD treatment Daxas in Canada and certain major EU countries, and will have exclusive commercialisation rights in the UK. ALLERGAN licensed SERENITY’s Phase III compound for nocturia, Ser-120, while Novartis began a strategic oncology collaboration with ARRAY focusing on MEK inhibitors. sanofi-aventis licensed CUREDM’s experimental diabetes treatment Pancreate. GLAXOSMITHKLINE is to work with CRUCELL on a second-generation malaria vaccine, and PFIZER announced an alliance with MICURX and CUMENCOR focusing on antibiotics designed to tackle drug-resistant tuberculosis in China.

7

Regulatory activity Both the FDA and EMA cleared OSI and ROCHE’s Tarceva for the additional indication of the maintenance therapy of advanced non-small cell lung cancer after platinum-based chemotherapy. In the EU, ASTRAZENECA and SHIONOGI’s statin Crestor was approved for the prevention of major cardiovascular events in high-risk patients. The FDA approved PURDUE’s reformulated version of the opioid analgesic OxyContin, designed to deter tampering and abuse. AstraZeneca and POZEN received a green light for their NSAID/PPI combination Vimovo, for arthritis patients at risk of developing NSAID-associated gastric ulcers. Also approved in the US were Novartis’ Zortress (Certican), for the prevention of organ rejection in adult kidney transplant recipients, and JOHNSON & JOHNSON’s Pancreaze, an enzyme designed to aid digestion in patients with e.g. cystic fibrosis. The EMA cleared GENMAB and GSK’s Arzerra, for the treatment of refractory chronic lymphocytic leukaemia, while Takeda’s DPP-4 inhibitor for Type II diabetes, Nesina, was approved in Japan and Canada licensed TEVA and PALADIN’s extended-cycle oral contraceptive Seasonique.

8

APRIL 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF Mergers & Acquisitions ABBOTT is to boost its emerging market presence with the $2.12bn+ acquisition of PIRAMAL’s domestic Healthcare Solutions business – a leader in the Indian branded generics market; it also began an alliance with ZYDUS CADILA to commercialise a portfolio of the latter’s products in 15 emerging markets and created a stand-alone Established Products Division. OSI accepted a higher, $4bn bid from ASTELLAS. ENDO is to acquire HEALTHTRONICS, a US provider of urological products and services, while VALEANT is buying ATON, which focuses on ophthalmology and orphan drugs. Licensing SANOFI-AVENTIS began a joint venture in Japan with NICHI-IKO, focusing on generics, and announced a licensing agreement with GLENMARK for the latter’s experimental chronic pain therapy, GRC 15300. SAGENT will market a portfolio of ACTAVIS’ specialty generic injectables in the US. TAKEDA is to co-promote its multiple myeloma therapy VELCADE in Japan with partner JOHNSON & JOHNSON, while FERRING acquired Lysteda, for heavy menstrual bleeding, for marketing in the US from XANODYNE and ZAMBON will co-market RECORDATI’s BPH drug Silodyx in France. PFIZER is to acquire ERGONEX’s terguride, in Phase II trials for pulmonary arterial hypertension, and also announced a "groundbreaking" collaboration with Washington University, which will focus on new uses for existing compounds. BOEHRINGER INGELHEIM began an alliance with MICROMET for an antibody against multiple myeloma, and ASTRAZENECA entered into a research agreement with the Global Alliance for TB Drug Development.

9

Regulatory activity The FDA approved: BAYER’s novel oral contraceptive Natazia (known as Qlaira in Europe); GENZYME’s new Pompe disease therapy Lumizyme; ALLERGAN’s Zymaxid for bacterial conjunctivitis; and CIPHER’s extended-release tramadol – though its marketing hinges on the outcome of a patent dispute between PURDUE and PAR. The agency declined to approve DAINIPPON SUMITOMO’s Stedesa as a treatment for epilepsy. The EMA cleared AMGEN’s Prolia for the treatment of post-menopausal osteoporosis in women at increased risk of fractures; GLAXOSMITHKLINE will be co-marketing the six-monthly injectable product in Europe. Canada approved NOVO NORDISK’s Victoza for Type II diabetes and Valeant’s Onsolis, an opioid analgesic for breakthrough pain in cancer patients.

10

MAY 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF Mergers & Acquisitions BIOVAIL and VALEANT announced a $3.3bn merger that will see the Canadian specialty firm buy its US peer; the new entity will be known as Valeant and run by the latter’s CEO (based in Barbados), but be domiciled in Canada. SANOFI-AVENTIS is to acquire TARGEGEN, which focuses on small molecule kinase inhibitors, for up to $560m; GLAXOSMITHKLINE bought Argentina’s LABORATORIOS PHOENIX; GILEAD is to buy CGI, another kinase specialist; and JOHNSON & JOHNSON acquired RESPIVERT, a British developer of inhaled therapies for pulmonary diseases. Licensing MERCK & CO announced a strategic collaboration with ADCOCK INGRAM, which will distribute and co-promote a number of its products in South Africa. PERRIGO acquired the US rights to TEVA’s OTC versions of sanofi-aventis’ Allegra and Allegra D-12 antihistamines, while BAUSCH & LOMB bought SIRION’s Zirgan, for herpetic keratitis. GSK will market MEDIVIR’s OTC cold sore treatment Xerclear in Europe, Japan, India and Australasia; TALECRIS and NOVARTIS will co-promote each other’s post-exposure rabies products; SIGMA-TAU is to commercialise DYAX’s ecallantide for hereditary angioedema in Europe, Russia, North Africa and the Middle East; and ALMIRALL will distribute BASILEA’s eczema therapy Toctino in Mexico and selected European markets. METABOLEX announced diabetes collaborations with both sanofi-aventis (GPR119 modulators) and J&J, while the latter also began a deal for DIAMYD’s Phase III GAD65 antigen-based therapy for Type I diabetes. ABBOTT licensed NEUROCRINE’s elagolix, for endometriosis, and Neurocrine also began a GPR119 agonist collaboration for Type II diabetes with BOEHRINGER INGELHEIM. Biovail licensed KYOWA HAKKO KIRIN’s istradefylline, for Parkinson’s disease, in the US and Canada, while HELSINN extended its collaboration with EISAI to include the development of a fixed-dose combination anti-emetic for the US market. GSK will market LABTEC’s topical cold sore patch; AESTUS gained worldwide rights to ASTELLAS’ FK614, for neuropathic pain; Boehringer Ingelheim licensed MARINOMED’s antiviral nasal spray; and LILLY will commercialise MARCADIA’s short-acting glucagon analogues for severe hypoglycaemia.

11

Sanofi-aventis began a major alliance with REGULUS for microRNA therapeutics for fibrosis, an HDM2/p53 cancer collaboration with ASCENTA, and an agreement with VIVALIS covering human monoclonal antibodies against infectious diseases. BAYER is to work with ONCOMED on stem cell therapeutics for cancer and TAURX on Alzheimer’s disease diagnostics and management tools. TAKEDA is to resume the production of flu vaccines using technology from BAXTER. FOREST will commercialise glucokinase activators from TRANSTECH for the treatment of diabetes; NYCOMED began a pain drug discovery collaboration with ESSEN; and ORASI will assist LUNDBECK with its development of CNS disorder compounds. BRISTOL-MYERS SQUIBB returned the rights to EXELIXIS’ XL184, a MET inhibitor in clinical trials for various tumour types, after the two companies were unable to agree on the appropriate clinical programme. Regulatory activity In the US, KOWA and Lilly launched statin Livalo; FERRING began marketing Lysteda, for cyclic heavy menstrual bleeding; and Takeda introduced ACTOplus met for Type II diabetes. The FDA granted additional indications to Novartis’ Tasigna (newly-diagnosed Ph+ chronic myeloid leukaemia) and ROCHE’s Lucentis (macular oedema following retinal vein occlusion). New approvals were issued for AMGEN’s Prolia, as a treatment for post-menopausal women with osteoporosis at high risk of fracture; Merck & Co’s Dulera for asthma in patients aged 12+; sanofi-aventis’ Jevtana for metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen; GSK’s Jalyn for benign prostatic hyperplasia; and Forest and MERZ’s Namenda XR for moderate-to-severe Alzheimer’s. The agency informed HUMAN GENOME SCIENCES and Novartis that it was unlikely to approve Zalbin for chronic hepatitis C using the dosing regimen outlined in the BLA. In the EU, GSK secured conditional approval for its renal cell carcinoma therapy Votrient, and the UK cleared GW PHARMACEUTICALS and Bayer’s Sativex, a cannabis-based product for the treatment of spasticity due to multiple sclerosis.

12

JUNE 2010 DEVELOPMENTS

COMPANY NEWS IN BRIEF Mergers & Acquisitions SANOFI-AVENTIS was rumoured to be considering a $20bn deal in the US, and speculation soon began to focus on troubled GENZYME. Later the French giant was said to have made an informal approach to the US biotech, which has been plagued by manufacturing problems; GLAXOSMITHKLINE was also reported to have made similar contact. MYLAN is to acquire BIONICHE, a global manufacturer of injectable pharmaceuticals, while LILLY is buying ALNARA, which develops protein therapeutics for metabolic diseases such as cystic fibrosis. APTUIT is to purchase GSK’s research operations in Italy, and PFIZER divested its Idun apoptosis R&D subsidiary to CONATUS, which is led by Idun’s former CEO. Licensing MERCK & CO signed a statement of mutual intent with SINOPHARM, which will initially focus on promoting Gardasil and other Merck vaccines in China. EISAI is to commercialise ARENA’s obesity drug lorcaserin in the US and also began a collaboration with AESTUS for the development of novel psychiatric therapeutics. GSK exercised its option to develop ANACOR’s antibiotic AN3365; ROCHE licensed NOVIMMUNE’s anti-IL17 MAb, for autoimmune disorders; WATSON is to develop ITERO’s recombinant follicle stimulating hormone, a biosimilar for female infertility; and BIOGEN IDEC licensed AMORFIX’s lead amyotrophic lateral sclerosis MAbs. SERVIER and GALAPAGOS announced a strategic alliance to develop novel small molecules for osteoarthritis. ACTIENT acquired six specialty pharmaceuticals from UCB, and LUNDBECK returned the US rights to GTC BIOTHERAPEUTICS’ ATryn, for hereditary antithrombin deficiency. MERCK KGaA licensed out EMD 670744, a Phase I cancer vaccine, to IMMUNOVACCINE. Regulatory activity The FDA approved SHIRE and NOVEN’s ADHD patch Daytrana for additional use in adolescents (ages 13-17). The EMA cleared BRISTOL-MYERS SQUIBB’s Orencia as a first-line biologic treatment after an inadequate response to a DMARD, in combination with methotrexate, in moderate-to-severe rheumatoid arthritis, while in the UK, ALLERGAN’s Botox was approved for the prophylaxis of headaches in

13

adults with chronic migraine. New products that passed regulatory review in the US included PURDUE’s Butrans, an opioid analgesic patch for moderate-to-severe chronic pain; DAIICHI SANKYO’s triple combination antihypertensive (second-line) Tribenzor; MONOSOL and PAR’s (Strativa) Zuplenza, an oral soluble film formulation of ondansetron for nausea and vomiting; and SHIONOGI’s Cuvposa, for chronic severe drooling in paediatric patients with neurological conditions such as cerebral palsy. The EC cleared NYCOMED’s Daxas for COPD; it will be co-promoted by Merck & Co in some countries. Also approved were RECORDATI’s statin Livazo, licensed from KOWA, and Allergan’s Ozurdex, for macular oedema. Russia became the first country to licence Merck KGaA’s pill for multiple sclerosis, cladribine, while Japan cleared ABRAXIS and OTSUKA’s Abraxane for breast cancer.

14

Sales through Retail Pharmacies (Twelve months to June 2010)

• NORTH AMERICA $241.1 billion up 5%

U.S.A. $222.1 billion up 5% CANADA $19.0 billion up 7%

• EUROPE (TOP 5) $110.6 billion up 2%

GERMANY $35.9 billion up 5% FRANCE $29.3 billion up 1% ITALY $16.5 billion up 1% SPAIN $15.1 billion up 3% UK $13.8 billion up 3%

• JAPAN (including hospitals) $82.0 billion up 4%

• CHINA (hospital) $29.3 billion up 28%

• LATIN AMERICA (TOP 4) $32.7 billion

BRAZIL $15.7 billion up 19% MEXICO $7.5 billion up 1% VENEZUELA $5.9 billion up 29% ARGENTINA $3.6 billion up 22%

• AUSTRALIA/NZ $9 billion up 6%

• The top 5 therapy classes at ATC3 level in the 12 months to

June 2010 were:

1. C10A – Cholesterol & trigly. regulators 2. A2B - Antiulcerants 3. N6A – Antidepressants & mood stabilisers 4. N5A - Antipsychotics 5. C9C – Angioten-II Antag, Plain

• The top 5 products in the 12 months to June 2010 were:

1. Lipitor 2. Plavix 3. Nexium 4. Seretide 5. Crestor

• The top 5 corporations in the 12 months to June 2010 were:

1. Pfizer 2. Novartis 3. AstraZeneca 4. Merck & Co 5. GlaxoSmithKline

15

Pakistan Pharmaceutical Market

16

MARKET OVERVIEW

The 1st Half 2010 ended with double digit growth for both MNCs and NAT. With the market size 131.827 billions, the industry grew exceptionally well with the phenomenal positive growth of +15.35% in Q2’10. Nationals remain dominant with the growth of +16.74% while Multinationals also grew with a double digit growth of +13.80% (MAT Q2 basis).

MAT QTRLY GROWTH 2007 TO 2010

10.0012.45

10.2011.46

11.42 11.86

17.8219.15 18.60 18.79

16.1915.43 15.3513.23

13.4515.62 16.08

13.2913.50

15.14

21.3723.25 22.26 21.55

18.65

17.24 16.74

12.47

9.549.39

14.1814.90 14.75

15.8113.51 13.41 13.80

9.416.92 10.48 7.96

8.53

0.00

10.00

20.00

30.00

Q1-07 Q2-07 Q3-07 Q4-07 Q1-08 Q2-08 Q3-08 Q4-08 Q1-09 Q2-09 Q3-09 Q4-09 Q1-10 Q2-10

GROWTH +/- %

Total NATIONAL MULTI-NATIONAL

The race is on between the multinationals and nationals. Nationals are gaining on multinational capturing share of 53.50% leaving multinational behind. However Multi-nationals still dominate unit market share with 50.25% as compared to Nationals 49.75% (based on Q2 2010).

17

NEW PRODUCT LAUNCHES The overall market dynamics are tilted in favor of national companies as they are continuously launching new products at a much faster rate than MNCs, a trend which is becoming increasingly evident. The value and total number of new products launched by the industry during Jan 2010 – Jun 2010 are as follows; Value Number of New Products MULTI-NATIONAL 67,111,217 11 NATIONAL 423,199,175 347 TOTAL 490,310,392 358

18

MULTINATIONAL VS NATIONAL ANALYSIS At present, there are 27 major MNC’s operating in the country with a share of almost 46.50% in value. A historical comparison of MNC’s share analysis over the last five years is shown in the chart below. The graph shows a clear gradual decline in share of MNC’s. MNC’s have lost 4.50% in value while in units they have lost 2.82%.

V A L U E %

46.50

47.13

48.71

49.64

51

53.50

52.87

51.29

50.36

49

5 15 25 35 45 55

2006

2007

2008

2009

2010

MNC NAT

U N I T %

53.07

52.66

52.28

51.31

50.25

46.93

47.34

47.72

48.69

49.75

5 15 25 35 45 55

2006

2007

2008

2009

2010

MNC NAT

The evolution index of MNC’s is 98.650 & NAT is 101.20 in the 1st Half of 2010.

19

DERIVED MARKET ANALYSIS As market share analysis is one of the key yardsticks to measure performance, it would be more pertinent to analyze Corporates in their own competing grounds. As would be observed below, there are major shifts for some companies creating new ranking dimensions to corporate listings. The results are tabulated as under:

The operating marketing size of GlaxoSmithKline is the largest among the top 20 Corporates followed by Searle, Novartis, Highnoon, Abbott and Barrett Hodgson. Thus, on the basis of the above and according to redefined market shares, the top 10 corporate rankings in descending order would be: Nestle, GlaxoSmithKline, Roche, Abbott, Bayer, Pfizer, Getz, Novartis and Sanofi-Aventis. However, Nestle sales are mainly from their consumer (non- pharmaceutical) products.

20

ACTIVE MARKET Fair deal of idea could be extracted from the following table, where the top 20 ATCs are analyzed under corporate contribution (Multinational & National), formulation and number of brands available.

Of the 20 TC analyzed the honors are nearly equally shared by MNC and Nationals as MNCs dominates in 9 ATCs while National dominate the rest 11.

21

Multi-Vitamin Price Increase Analysis

As we all know that MOH granted a limited price increase on certain

categories of drugs i.e. Vitamin B complex (A11E) in the month of April

2010.

IMS has analyzed the pre price increase situation of this segment and the

post price increase behavior of the same.

The price as we all know was granted to a total market of A11E in terms

of units was 35.29 Mn as on (Jan 2010 MAT Basis). It is interesting to

note that although the price increase took place from 1st April 2010 but

the increase in sales already had taken place from March 2010 i.e., a

month earlier.

The main beneficiaries of the price increase were mostly MNCs as they

hold the major share in this segment. The analysis shows that the total

market that was hardly growing -0.85% (Feb Vs Jan 2010) before March

abruptly went up by 48 % (March Vs Feb 2010). However this was not

sustained as following month slowed down the growth to 27% (April Vs

March) and -25% (May Vs April) and it was -14% (June Vs May 2010).

Hence the negative performance of this segment tailed off the huge

growth we had observed in March and April.

22

MARKET COMMENTARY (MAT Q2 2010 Vs MAT Q2 2009)

LEADING 20 CORPORATES The overall market jumped to 131-billion rupee mark with a growth of +15.35% on MAT Q2 basis. The top 20 Corporates crossed the 1 billion mark, of these 10 are multinationals and 10 nationals respectively, the top 20 Corporates contribute 62.86%. GSK alone contributes 10.15% of the total market. The first three positions remained in the same hands those of GlaxoSmithKline, Abbott and Pfizer respectively. Novartis, Sanofi Aventis, Getz, Bayer and ICI retained their positions. In the top 20 slot Sami clinched the 7th position, whereas Bosch moved two positions up from 14th to 12th clinching Highnoon’s position, Searle moved three positions up from 11th to 8th position clinching Sami’s position, Nestle moved four positions up from 18th to 14th clinching Bosch’s position and Barrett Hodgson also moved up one position from 19th to 18th position clinching Nestle position. The Corporates managing to grow more than the market (having evolution indices above 100) are Abbott, Sanofi Aventis, Getz, Sami, Searle, Bosch, Highnoon, Nestle, Bayer and Barrett Hodgson. Amongst the top 20 Corporates, Nestle, was the fastest growing company (+50.20%) followed by Searle (+47.18%), Bosch (+38.75%), and Sami (+22.44%).

LEADING 20 MULTINATIONAL CORPORATES Although the MNC’s grew with double digit +13.80% they gained around .63% share in value to the national companies at MAT Q2 - 2010 as compared to MAT Q2 – 2009. Total market size of MNC moved from Rs. 53.86 Bn to Rs 61.29 Bn. The top 7 slots remained in the same hands while there were shifts in rankings in the following league of MNCs Club as Nestle moved two position up from 10th to 8th , Bayer one position down from 8th to 9th , BMS one position down from 9th to 10th , Chiesi one position up from 15th to 14th , Servier one position up from 16th to 15th and Stiefel two position down from 14th to 16th. The companies who have maintained their position are GSK, Abbott, Pfizer, Novartis, Sanofi Aventis, Roche, Merck, Johnson & Johnson, Eli Lilly, Reckitt Benckiser, Alcon, Novo Nordisk Schering Plough. The fastest growing corporate is Nestle with a growth of +50.20% followed by Abbott 24.05%, Novo Nordisk +23.98%, Sanofi Aventis +18.60%, and Alcon +16.32%.

23

LEADING 20 NATIONAL CORPORATES The national Corporates are consistently gaining share in the market, growing at +16.74%. The national market has a value of Rs. 70.53 billions with a share of 53.50%. In the top 10 slot Searle has clinched Hilton’s position by moving up from 4th to 3rd, Bosch moving up from 7th to 5th, Barrett Hodgson moving up from 9th to 8th (clinched OBS position). The companies that maintained their position in the top 20’s are: Getz, Sami, ICI, Indus, Nabiqasim, High-Q Int’l, and Macter. Within the top 20 movement in slots in last one year MAT Q2 2010 Vs MAT Q2 2009 are as follows Amongst the top 20 nationals, the fastest growing were Geofman (+72.42), Searle (+47.18), Bosch (+38.75%), Global (+32.44), CCL (+28.42%), Sami (+22.44), Atco (+21.52%), and Nabiqasim (+20.40%).

Rank Movement S # COMPANIES From To

1 Searle 4 3

2 Hilton 3 4

3 Bosch 7 5

4 AGP 5 7

5 Highnoon 5 6

6 AGP 6 7

7 Barrett Hodgson 9 8

8 OBS 8 9

9 CCL 13 12

10 Atco 12 13

11 Geofman 27 14 12 Ferozsons 14 15 13 Platinum 15 19 14 Global 25 20

24

LEADING 20 ATC’S All the leading top 20 ATC’s (at 3rd level) have crossed the Rupees 1 billion mark. The top 4 ATC’s remain the same however the ATC’s that underwent rank movements are;

Rank Movement TCIII DESCRIPTION From To V06C INFANT FORMULAS 7 5

A02B ANTIULCERANTS 5 6

N02B NON-NARCOTIC ANALGESICS 6 7

J01F MACROLIDES & SIMILAR TYPE 9 8

B03A HEAMATINICS, IRON & COMBS 8 9

A11E VITAMINS B COMPLEX 17 13

N05C TRANQULLIZERS 10 11

J05B ANTIVIRALS EXCL ANTI-HIV 13 12

N05C TRANQULLIZERS 13 14

N03A ANTI-EPILEPTICS 14 15

N06A ANTIDEPRESS. & MOOD STAB. 18 16

A10H SULPHONYLUREAS A-DIABS 15 17

C07A BETA BLOCKING AGENT PLAIN 16 18 R05C EXPECTORANTS 22 19 C10A CHOLEST&TRIGLY.REGULATOR 21 20

Among the top 20 ATCs, the fastest growing ATC were Infant formulas (+47.94%), followed by Vitamin B Complex (+29.11), Expectorants (+25.84%), Cholest & Triglycride Regulator (+18.64%), and Anti-Epileptics (18.34%). All the ATC’s had positive growth.

25

LEADING 20 PRODUCTS Augmentin is heading the leading top 20 products table, by a very big margin of 1.42 billion ahead of its next product with a growth of +14.19%. Again the Multinationals are leading the top 20 products list with 15 products against 5 products of Nationals.

Among the leading 20 products, 7 products belong to GSK, 2 each products belong to Roche and Sami, while one product each belongs to Parke Davis, Bristol Myers Squibb, Sanofi-Aventis, Abbott, Nestle, Hilton, Getz, Eli Lilly , and Meiji. The top 20 products contribute 13.28% in the total market. Among the top 20 highest growth was seen in Meiji (+51.46%) followed by Lactogen (+42.26%), Panadol (+34.84), Oxidil (+24.57), Brufen (+24.38%), Pegasys( +21.55%), and Humulin 70/30 (+20.63).

Besides the above out of the top 20, 17 products show double - digit growth this includes Augmentin, Amoxil, Velosef, Pegasys, Flagyl, Brufen, Lactogen, Meiji, Risek, Humulin 70/30, Rocephin, Novidat, Ampiclox, Panadol, and Ventolin.

Among the leading 20 products, 8 belong to Anti-infective class, 4 to Alimentary Tract System, 2 to Infant Milk, 2 to Non Narcotic Analgesics, 1 each to Interferons, topical Corticosteroids, Antirheumatic topical and Anti Asthma.

LEADING 20 NEW PRODUCTS National Companies have a major dominance in the new product market (product < 25 months old) as 15 out of the top 20 belong to them. 3 products belonged to Sami, two products each belonged to Novartis, GSK, Getz and High-Q International. While one each to Meiji, Searle, LG LifeScience, Merck, Himont, Ferozsons, CCL, Global, and Almirall. “Qalsan D” is the leading product with a sales value of Rupees 123 millions and having 1.99% share from the total new products market. In terms of market share within new products, Meiji Big achieved 1.55%, followed by Rotec achieved 1.32% , and Infanrix Hexa (1.13%).

26

LEADING 20 SINGLE MOLECULES The single molecule market stood at Rs. 68.76 billion with a growth of +12.88%. All the leading top 20 Single molecules have crossed the Rupees 1 billion mark. Among the top 20 only Diclofenac, Ceftriaxone, Ciprofloxacin, Cefixime, Omeprazole, Amoxicillin and Montelukast maintained their ranks, while significant changes were seen in the ranking of the remaining molecules, further shown in the below table;

Rank Movement S.No MOLECULES From To

1 PARACETAMOL 8 7 2 CEFRADINE 7 8 3 LEVOFLOXACIN 10 9 4 MECOBALMIN 9 10 5 LEVOFLOXACIN 10 9 6 ESOMEPRAZOLE 19 11 7 CLARTHROMYCIN 15 12 8 METRONIDAZOLE 14 13 9 IBUPROFEN 16 14

11 CEFOTAXIME 13 15 12 PEGINTERFERON ALFA-2A 17 16 13 GLIMEPIRIDE 18 17 14 MEFENAMIC ACID 11 18

15 INTERFERON ALFA-2B 12 19 Highest growth was seen in Esomeprazole (+37.65%), Paracetamol (+27.04), Metronidazole (+24.46%), Cefixime (+23.21%), Clarithromycin (+22.83%), and Peginterferon Alfa 2A (+21.55%).

L20 CORP

Q2 Q22010 2009

TOTAL 131,827,642,331 100.00 15.35 100.00 114,280,703,492 100.00 18.60 100.00

1 1 GLAXOSMITHKLINE 13,385,426,849 10.15 13.79 98.64 11,763,279,746 10.29 92.422 2 ABBOTT 7,991,008,226 6.06 24.05 107.54 6,441,795,628 5.64 18.75 100.133 3 PFIZER 6,606,922,473 5.01 4.20 90.33 6,340,652,459 5.55 14.29 96.364 4 NOVARTIS 5,835,091,994 4.43 9.05 94.53 5,351,079,663 4.68 19.80 101.015 5 SANOFI-AVENTIS 5,273,855,967 4.00 18.60 102.81 4,446,742,915 3.89 14.55 96.586 6 GETZ 4,903,159,859 3.72 17.96 102.26 4,156,601,200 3.64 24.78 105.207 8 SAMI 4,148,441,689 3.15 22.44 106.14 3,388,079,613 2.96 31.98 111.288 11 SEARLE 3,962,671,613 3.01 47.18 127.59 2,692,386,931 2.36 31.12 110.559 7 ROCHE 3,944,647,272 2.99 9.93 95.30 3,588,324,433 3.14 24.35 104.85

10 9 MERCK 3,490,097,342 2.65 10.75 96.01 3,151,378,740 2.76 18.27 99.7211 10 HILTON 3,430,695,024 2.60 12.27 97.33 3,055,794,253 2.67 21.44 102.3912 14 BOSCH 2,853,204,068 2.16 38.75 120.28 2,056,430,761 1.80 32.58 111.7813 12 HIGHNOON 2,488,579,411 1.89 17.05 101.47 2,125,999,830 1.86 12.70 95.0214 18 NESTLE 2,463,555,066 1.87 50.20 130.20 1,640,219,835 1.44 1.02 85.1715 15 BAYER 2,332,359,915 1.77 15.57 100.18 2,018,206,023 1.77 12.22 94.6216 13 AGP 2,217,143,774 1.68 5.76 91.68 2,096,379,660 1.83 11.93 94.3717 16 BRISTOL MYERS SQUI 2,024,625,057 1.54 10.90 96.14 1,825,635,848 1.60 17.48 99.0518 19 BARRETT HODGSON 1,903,008,127 1.44 17.37 101.75 1,621,339,245 1.42 17.36 98.9519 17 OBS 1,892,923,916 1.44 7.87 93.51 1,754,781,399 1.54 7.82 90.9120 20 I.C.I 1,714,810,013 1.30 14.59 99.33 1,496,534,563 1.31 15.57 97.44

Others 48,965,414,676 37.14 0.00 0.00 43,269,060,747 37.85 0.00 0.00

Pakistan Market

VALUE SHARE %GROWTH + % over Q2 2008 EVOL

LEADING 20 CORPORATES Valuewise in Pak Rupees

RANKCORPORATES

MAT Q2 2010 MAT Q2 2009

VALUE SHARE %GROWTH + % over Q2 2009 EVOL

Page 1

Q2 Q22010 2009

Total 131,827,635,902 100.00 15.35 100.00 114,280,703,342 100.00 18.60 100.00

NATIONAL 70,530,169,769 53.50 16.74 101.20 60,417,419,376 52.87 22.26 103.08

1 1 GETZ 4,903,159,859 6.95 17.96 101.05 4,156,601,200 6.88 24.78 102.062 2 SAMI 4,148,441,689 5.88 22.44 104.89 3,388,079,613 5.61 31.98 107.953 4 SEARLE 3,962,671,613 5.62 47.18 126.08 2,692,386,931 4.46 31.12 107.244 3 HILTON 3,430,695,024 4.86 12.27 96.17 3,055,794,253 5.06 21.44 99.325 7 BOSCH 2,853,204,068 4.05 38.75 118.85 2,056,430,761 3.40 32.58 108.446 5 HIGHNOON 2,488,579,411 3.53 17.05 100.27 2,125,999,830 3.52 12.70 92.187 6 AGP 2,217,143,774 3.14 5.76 90.60 2,096,379,660 3.47 11.93 91.558 9 BARRETT HODGSON 1,903,008,127 2.70 17.37 100.54 1,621,339,245 2.68 17.36 95.999 8 OBS 1,892,923,916 2.68 7.87 92.41 1,754,781,399 2.90 7.82 88.19

10 10 I.C.I 1,714,810,013 2.43 14.59 98.16 1,496,534,563 2.48 15.57 94.5211 11 INDUS 1,568,936,950 2.22 16.99 100.21 1,341,129,291 2.22 34.73 110.2012 13 CCL 1,541,516,428 2.19 28.42 110.00 1,200,412,359 1.99 34.50 110.0113 12 ATCO 1,523,281,560 2.16 21.52 104.10 1,253,488,224 2.07 34.67 110.1514 27 GEOFMAN 1,321,371,317 1.87 72.42 147.70 766,376,353 1.27 27.64 104.4015 14 FEROZSONS 1,216,157,556 1.72 19.55 102.40 1,017,320,568 1.68 16.01 94.8916 16 NABIQASIM 1,183,948,228 1.68 20.40 103.14 983,334,060 1.63 9.07 89.2117 17 HIGH-Q INTL 1,145,118,766 1.62 18.35 101.38 967,587,515 1.60 33.84 109.4718 18 MACTER 1,142,667,985 1.62 19.68 102.52 954,799,074 1.58 12.10 91.6919 15 PLATINUM 1,123,453,582 1.59 12.54 96.40 998,276,268 1.65 23.11 100.7020 25 GLOBAL 1,083,361,700 1.54 32.44 113.45 818,021,632 1.35 2.31 83.68

Others 28,165,718,203 39.95 25,672,346,577 42.50

Pakistan Market

VALUE SHARE %GROWTH + % over Q2

EVOL

LEADING 20 NATIONAL CORPORATES Q2 - 2010Valuewise in Pak Rupees

RANKCORPORATES

MAT Q2 2010 MAT Q2 2009

VALUE SHARE %GROWTH + % over Q2

EVOL

Q2 Q22010 2009

Total 131,827,635,902 100.00 15.35 100.00 114,280,703,342 100.00 18.60 100.00

MULTI-NATIONAL 61,297,472,562 46.50 13.80 98.65 53,863,284,116 47.13 14.75 96.75

1 1 GLAXOSMITHKLINE 13,385,426,849 21.84 13.79 99.99 11,763,279,746 21.84 9.61 95.522 2 ABBOTT 7,991,008,226 13.04 24.05 109.00 6,441,795,628 11.96 18.75 103.493 3 PFIZER 6,606,922,473 10.78 4.20 91.56 6,340,652,459 11.77 14.29 99.604 4 NOVARTIS 5,835,091,994 9.52 9.05 95.82 5,351,079,663 9.93 19.80 104.405 5 SANOFI-AVENTIS 5,273,855,967 8.60 18.60 104.22 4,446,742,915 8.26 14.55 99.826 6 ROCHE 3,944,647,272 6.44 9.93 96.60 3,588,324,433 6.66 24.35 108.367 7 MERCK 3,490,097,342 5.69 10.75 97.32 3,151,378,740 5.85 18.27 103.068 10 NESTLE 2,463,555,066 4.02 50.20 131.98 1,640,219,835 3.05 1.02 88.039 8 BAYER 2,332,359,915 3.80 15.57 101.55 2,018,206,023 3.75 12.22 97.79

10 9 BRISTOL MYERS SQUI 2,024,625,057 3.30 10.90 97.45 1,825,635,848 3.39 17.48 102.3711 11 JOHNSON & JOHNSON 1,492,618,271 2.44 13.26 99.52 1,317,887,339 2.45 8.10 94.2012 12 ELI LILLY 1,259,756,220 2.06 14.81 100.89 1,097,207,600 2.04 17.26 102.1913 13 RECKITT BENCKISER 952,189,381 1.55 7.36 94.34 886,913,768 1.65 11.24 96.9414 15 CHIESI FARMACEUTIC 794,433,614 1.30 9.68 96.37 724,344,199 1.34 14.47 99.7515 16 SERVIER 771,017,383 1.26 15.68 101.65 666,508,721 1.24 11.99 97.6016 14 STIEFEL 751,125,175 1.23 -10.74 78.43 841,521,078 1.56 20.98 105.4317 17 OTSUKA 652,746,194 1.06 2.62 90.17 636,077,920 1.18 34.47 117.1818 18 ALCON 375,285,463 0.61 16.32 102.22 322,620,162 0.60 8.13 94.2219 19 NOVO NORDISK 374,247,287 0.61 23.98 108.95 301,854,498 0.56 24.34 108.3620 20 SCHERING PLOUGH 315,798,739 0.52 8.63 95.45 290,714,924 0.54 15.20 100.39

Others 210,664,674 0.33 0.00 0.00 210,318,617 0.38 0.00 0.00

LEADING 20 MULTINATIONAL CORPORATESValuewise in Pak Rupees

RANKCORPORATES

MAT Q2 2010 MAT Q2 2009

VALUE SHARE %GROWTH + % over Q2 2009

EVOL VALUE SHARE %GROWTH + % over Q2 2008

EVOL

Pakistan Market

Q2 Q22010 2009

TOTAL 131,827,642,331 100.00 15.35 100.00 114,280,703,492 100.00 18.60 100.00

1 1 J01D CEPHALOSPORINS & COMBS 10,860,756,146 8.24 13.64 98.52 9,557,050,738 8.36 22.49 103.282 2 M01A ANTIRHEUMATIC NON-STEROID 7,112,728,683 5.40 12.79 97.77 6,306,358,741 5.52 17.66 99.203 3 J01C BROAD SPECTRUM PENICILLIN 6,183,677,534 4.69 16.32 100.83 5,316,317,215 4.65 10.71 93.354 4 J01G FLUOROQUINOLONES 5,688,301,371 4.31 13.06 98.01 5,031,131,981 4.40 21.76 102.665 7 V06C INFANT FORMULAS 5,388,465,867 4.09 47.94 128.25 3,642,249,808 3.19 12.71 95.036 5 A02B ANTIULCERANTS 5,379,200,286 4.08 15.56 100.18 4,654,706,657 4.07 23.79 104.377 6 N02B NON-NARCOTIC ANALGESICS 4,034,716,205 3.06 9.18 94.64 3,695,589,294 3.23 14.93 96.908 9 J01F MACROLIDES & SIMILAR TYPE 2,724,628,035 2.07 15.69 100.29 2,355,175,729 2.06 19.68 100.919 8 B03A HAEMATINICS,IRON & COMBS 2,717,423,748 2.06 13.89 98.73 2,385,991,852 2.09 23.66 104.26

10 10 A12A CALCIUM 2,227,906,353 1.69 11.93 97.03 1,990,457,533 1.74 18.92 100.2611 11 R06A ANTIHISTAMINES SYSTEMIC 2,148,228,722 1.63 16.76 101.22 1,839,810,929 1.61 8.83 91.7612 12 J05B ANTIVIRALS EXCL ANTI-HIV 2,036,480,421 1.54 12.81 97.79 1,805,288,110 1.58 31.31 110.7113 17 A11E VITAMIN B COMPLEX 1,906,654,597 1.45 29.11 111.92 1,476,807,044 1.29 18.37 99.8114 13 N05C TRANQUILLIZERS 1,896,771,816 1.44 5.98 91.87 1,789,778,239 1.57 5.43 88.8915 14 N03A ANTI-EPILEPTICS 1,877,215,261 1.42 18.34 102.59 1,586,233,694 1.39 28.80 108.5916 18 N06A ANTIDEPRESS.& MOOD STAB. 1,718,532,789 1.30 16.90 101.34 1,470,108,662 1.29 20.78 101.8317 15 A10H SULPHONYLUREA A-DIABS 1,714,252,656 1.30 13.96 98.79 1,504,284,582 1.32 11.71 94.1918 16 C07A BETA BLOCKING AGENT PLAIN 1,687,201,223 1.28 12.52 97.54 1,499,510,281 1.31 14.31 96.3819 22 R05C EXPECTORANTS 1,627,874,482 1.23 25.84 109.09 1,293,567,405 1.13 19.66 100.8920 21 C10A CHOLEST&TRIGLY.REGULATOR 1,593,781,404 1.21 18.64 102.84 1,343,425,456 1.18 24.14 104.67

Others 61,302,844,732 46.51 53,736,859,542 47.02

LEADING 20 THERAPEUTIC CLASSESValuewise in Pak Rupees

RANKTC III CODE THERAPEUTIC CLASS

MAT Q2 2010 MAT Q2 2009

VALUE SHARE %GROWTH + % over Q2 EVOL

Pakistan Market

EVOL VALUE SHARE %GROWTH + % over Q2

Q2 Q2

2010 2009 TOTAL 131,824,925,805 100.00 15.36 100.00 114,276,539,016 100.00 18.61 100.00

1 1 AUGMENTIN GLAXOSMITHKLINE AMOXICILLIN / CLAVULANIC ACID J01C 2,626,536,468 1.99 14.19 98.99 2,300,221,157 2.01 17.09 98.722 2 AMOXIL GLAXOSMITHKLINE AMOXICILLIN J01C 1,203,167,280 0.91 13.33 98.24 1,061,680,408 0.93 12.38 94.753 4 VELOSEF BRISTOL MYERS SQUIB CEFRADINE J01D 1,157,060,078 0.88 11.72 96.84 1,035,711,853 0.91 25.92 106.164 5 PEGASYS ROCHE PEGINTERFERON ALFA-2A J05B 1,130,415,043 0.86 21.55 105.37 930,023,252 0.81 41.47 119.285 6 FLAGYL SANOFI AVENTIS METRONIDAZOLE J08B 969,155,793 0.74 18.34 102.59 818,927,987 0.72 27.23 107.276 7 BRUFEN ABBOTT IBUPROFEN M02A 966,084,339 0.73 24.38 107.82 776,726,355 0.68 25.02 105.417 3 PONSTAN PARKE DAVIS MEFENAMIC ACID N02B 898,944,963 0.68 -14.42 74.19 1,050,446,222 0.92 17.72 99.258 13 LACTOGEN NESTLE INFANT MILKS V06C 838,226,036 0.64 42.26 123.33 589,204,753 0.52 22.55 103.329 19 MEIJI MILK MEIJI INFANT MILKS V06C 779,554,424 0.59 51.46 131.30 514,687,796 0.45 30.43 109.97

10 9 RISEK GETZ OMEPRAZOLE A02B 729,502,687 0.55 18.90 103.07 613,564,410 0.54 34.07 113.0411 8 METHYCOBAL EISAI MECOBALAMIN A11F 700,111,943 0.53 5.73 91.66 662,167,355 0.58 22.49 103.2712 14 HUMULIN 70/30 ELI LILLY INSULIN HUMAN BASE A10C 698,586,738 0.53 20.63 104.58 579,097,316 0.51 21.33 102.3013 10 ROCEPHIN ROCHE CEFTRIAXONE J01D 673,838,803 0.51 11.53 96.69 604,150,499 0.53 25.03 105.4114 12 NOVIDAT SAMI CIPROFLOXACIN J01G 670,708,431 0.51 13.50 98.39 590,936,435 0.52 30.04 109.6415 15 AMPICLOX GLAXOSMITHKLINE AMPICILLIN / CLOXACILLIN J01C 636,816,004 0.48 10.21 95.54 577,796,990 0.51 -9.78 76.0716 23 PANADOL GLAXOSMITHKLINE PARACETAMOL N02B 591,332,613 0.45 34.84 116.89 438,553,348 0.38 0.18 84.4717 17 BETNOVATE N GLAXOSMITHKLINE BETAMETHASONE / NEOMYCIN D07B 580,041,866 0.44 7.57 93.25 539,226,566 0.47 13.35 95.5618 18 ZANTAC GLAXOSMITHKLINE RANITIDINE A02B 565,676,603 0.43 9.16 94.63 518,192,503 0.45 13.36 95.5719 20 VENTOLIN GLAXOSMITHKLINE SALBUTAMOL R03A 551,145,574 0.42 8.79 94.31 506,610,824 0.44 8.10 91.1420 26 OXIDIL SAMI CEFTRIAXONE J01D 538,515,577 0.41 24.57 107.99 432,303,221 0.38 50.44 126.84

Others 114,319,504,542 86.72 99,136,309,766 86.74

SHARE %GROWTH + % over Q2 2008

EVOL

Pakistan Market

SHARE %GROWTH + % over Q2 2009

EVOL VALUE

LEADING 20 PRODUCTS Valuewise in Pak Rupees

RANKPRODUCTS MANUFACTURER MOLECULE TC III

MAT Q2 2010 MAT Q2 2009

VALUE

Q2 Q22010 2009

TOTAL 131,827,635,902 100.00 15.35 100.00 114,280,703,342 100.00 18.60 100.00

SINGLE MOLECULE TOTAL 89,746,234,022 68.08 12.88 97.86 79,504,003,740 69.57 18.51 99.92

1 1 DICLOFENAC 3,120,399,307 3.48 9.46 96.97 2,850,721,542 3.59 14.38 96.522 2 CEFTRIAXONE 2,940,416,834 3.28 17.28 103.90 2,507,116,129 3.15 25.20 105.653 3 CIPROFLOXACIN 2,733,530,026 3.05 13.40 100.46 2,410,588,486 3.03 19.47 100.824 4 CEFIXIME 2,341,466,003 2.61 23.21 109.14 1,900,457,222 2.39 34.56 113.555 5 OMEPRAZOLE 1,972,503,299 2.20 12.76 99.89 1,749,240,175 2.20 27.31 107.436 6 AMOXICILLIN 1,912,873,362 2.13 14.68 101.60 1,667,958,972 2.10 9.32 92.257 8 PARACETAMOL 1,773,331,665 1.98 27.04 112.54 1,395,854,771 1.76 14.51 96.638 7 CEFRADINE 1,639,842,743 1.83 7.01 94.80 1,532,387,582 1.93 14.06 96.259 10 LEVOFLOXACIN 1,535,520,915 1.71 12.98 100.09 1,359,101,375 1.71 34.54 113.53

10 9 MECOBALAMIN 1,495,665,281 1.67 8.46 96.08 1,378,983,260 1.73 20.35 101.5611 19 ESOMEPRAZOLE 1,232,029,131 1.37 37.65 121.94 895,030,360 1.13 59.44 134.5412 15 CLARITHROMYCIN 1,212,868,149 1.35 22.83 108.81 987,448,286 1.24 39.87 118.0313 14 METRONIDAZOLE 1,204,474,425 1.34 19.52 105.88 1,007,791,358 1.27 17.00 98.7314 16 IBUPROFEN 1,158,995,096 1.29 24.46 110.26 931,192,002 1.17 22.23 103.1415 13 CEFOTAXIME 1,153,418,559 1.29 4.99 93.00 1,098,641,904 1.38 11.28 93.9016 17 PEGINTERFERON ALFA-2A 1,130,415,043 1.26 21.55 107.68 930,023,252 1.17 41.47 119.3817 18 GLIMEPIRIDE 1,073,652,820 1.20 16.87 103.54 918,641,820 1.16 19.79 101.0818 11 MEFENAMIC ACID 1,054,845,865 1.18 -13.83 76.33 1,224,179,300 1.54 15.71 97.6419 12 INTERFERON ALFA-2B 993,955,668 1.11 -10.49 79.30 1,110,399,507 1.40 12.22 94.7020 20 MONTELUKAST 979,694,391 1.09 13.07 100.16 866,466,799 1.09 34.90 113.83

Others 42,081,401,880 63.58 34,776,699,602 63.86

LEADING 20 MOLECULES Valuewise in Pak Rupees

RANKMOLECULE

MAT Q2 2010 MAT Q2 2009

VALUE SHARE %GROWTH + % over Q2 2009

EVOL

Pakistan Market

VALUE SHARE %GROWTH + % over Q2 2008

EVOL

RANKQ2 2010 VALUE SHARE % SHARE % IN ATC VALUE SHARE % SHARE % IN ATC

SELECTED TOTAL 6,202,267,521 100 1,765,883,693 100

1 QALSAN-D NOVARTIS COLECALCIFEROL / CALCIUM A12A 123,135,965 1.99 5.52 0 0.00 0.002 MEIJI BIG MEIJI INFANT MILKS V06C 96,025,454 1.55 1.78 34,968,695 1.98 0.963 ROTEC SEARLE DICLOFENAC / MISOPROSTOL M01A 82,091,400 1.32 1.15 27,536,524 1.56 0.444 INFANRIX HEXA GLAXOSMITHKLINE VACCINE, HEPATITIS B SURFACE ANTIGE J07B 70,160,922 1.13 56.35 40,819,976 2.31 56.495 IVF-C LG LIFE SCIENCE CHORIONIC GONADOTROPHIN G03G 65,350,951 1.05 12.55 0 0.00 0.006 ESKEM HIGH Q INT'L ESOMEPRAZOLE A02B 65,134,782 1.05 1.21 20,765,037 1.18 0.457 ARCEVA SAMI ARTEMETHER / LUMEFANTRINE P01D 62,254,716 1.00 4.53 22,033,785 1.25 1.858 POLYBION Z MERCK ASCORBIC ACID / FOLIC ACID / VIT E A11E 61,192,811 0.99 3.20 28,428,951 1.61 1.939 RITHMO SAMI CLARITHROMYCIN J01F 61,063,005 0.98 2.24 30,651,101 1.74 1.30

10 EPITIZE HIMONT HERBAL A15A 57,687,082 0.93 8.13 34,181,933 1.94 5.3911 CENTAURUS FEROZSONS ENTECAVIR J05B 55,333,216 0.89 2.71 8,203,860 0.46 0.4512 TASIGNA NOVARTIS NILOTINIB L01X 54,987,520 0.89 8.92 90,440 0.01 0.0213 BISLERI-S SAMI IRON METAL B03A 51,747,176 0.83 1.90 22,144,207 1.25 0.9314 TACAVIR CCL ENTECAVIR J05B 51,592,453 0.83 2.53 8,092,000 0.46 0.4515 REFRON GLOBAL INTERFERON ALFA-2B L03B 45,243,636 0.73 4.19 2,867,729 0.16 0.2316 TAMSOLIN GETZ TAMSULOSIN G04C 41,104,676 0.66 11.45 13,488,176 0.76 4.8317 CIDINE ALMIRALL CINITAPRIDE A03F 39,589,229 0.64 2.80 6,801,889 0.39 0.5318 CIPVAL GLAXOSMITHKLINE CIPROFLOXACIN J01G 39,323,521 0.63 0.69 0 0.00 0.0019 QUPRON HIGH Q INT'L CIPROFLOXACIN J01G 38,103,180 0.61 0.66 0 0.00 0.0020 INSUGET 70/30 GETZ INSULIN HUMAN BASE A10C 38,029,746 0.61 2.69 9,094,086 0.51 0.71

Others 5,797,627,088 80.70 1,455,715,304 82.43

MAT Q2 2010 MAT Q2 2009

Pakistan Market

LEADING 20 NEW PRODUCTS Valuewise in Pak Rupees

PRODUCTS MANUFACTURER MOLECULE NAME ATC III

MARKET 2004 2005 2006 2007 2008 2009 2010

MULTI-NATIONAL 55.14 53.64 51.00 49.64 48.71 47.13 46.50

NATIONAL 44.86 46.36 49 50.36 51.29 52.87 53.5

MARKET 2004 2005 2006 2007 2008 2009 2010

MULTI-NATIONAL 54.91 54.53 53.07 52.66 52.28 51.31 50.25

NATIONAL 45.09 45.47 46.93 47.34 47.72 48.69 49.75

MNC & NATIONAL SHARE IN PAKISTAN PHARMA MARKET (MAT 2Q , 2004-2010)

% SHARE IN VALUE

% SHARE IN UNITS

Pakistan Market

EXECUTIVE SUMMARY1ST HALF 2010

Feed back form Dear Client: We are pleased to present you the Executive Summary 1st Half 2010 report. Your valuable feedback on our earlier reports has helped us incorporate several new analyses in the subsequent reports. We request you to provide your feedback and rate the report on the following parameters. Parameter Excellent Very Good Good Average Poor Content of the report

Presentation style

Value addition to your work

Suggestions are most welcome

Please address this page to Mr. A.G. Meghany and fax it back to us on 92-21-34314651 From: Name & Designation: __________________________________ Company: __________________________________

This report is for the exclusive use of IMS subscriber. No part of this report should be reported or reproduced without the prior written permission of IMS Switzerland.